Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 2, 2012, Pages 135-143

  Price, R S ^a   Cavazos, D A ^a   De Angel, R E ^a   Hursting, S D ^a   DeGraffenried, L A ^a  

^a The University of Texas at Austin   (United States)

Author keywords

EMT; invasion; obesity

Indexed keywords

BETA CATENIN; GELATINASE B; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; TESTOSTERONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UVOMORULIN; VASCULOTROPIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; INTERLEUKIN-6; LEPTIN; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, OBESE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATE; PROSTATIC NEOPLASMS; TESTOSTERONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861234323     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2011.54     Document Type: Article

References (32)

1. SEER Research Data 2010. http://seer.cancer.gov/statfacts/ html/prost.html#survival
2. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007; 109: 1192-1202
3. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM et al. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer 2007; 110: 2691-2699
4. Freedland SJ, Bañez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 2009; 12: 259-263
5. Hursting S, Nunez N, Varticovski L, Vinson C. The Obesity- Cancer link: lessons learned from a fatless mouse. Cancer Res 2007; 67: 2391-2393
6. Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol 2009; 182: 1621-1627
7. Fenton JI, Nuñ ez NP, Yakar S, Perkins SN, Hord NG, Hursting SD. Diet-induced adiposity alters the serum profile of inflammation in C57BL/6N mice as measured by antibody array. Diabetes Obes Metab 2009; 11: 343-354
8. Efstathiou JA, Chen MH, Renshaw AA, Loffredo MJ, D'Amico AV. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer 2007; 109: 1493-1498
9. Narayanan NK, Nargi D, Horton L, Reddy BS, Bosland MC, Narayanan BA. Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib. Prostate 2009; 69: 133-141
10. Saikali Z, Setya H, Singh G, Persad S. Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells. Cancer Cell Int 2008; 8: 10
11. He H, Yang X, Davidson AJ, Wu D, Marshall FF, Chung LW et al. Progressive epithelial to mesenchymal transitions in ARCaP E prostate cancer cells during xenograft tumor formation and metastasis. Prostate 2010; 70: 518-528
12. Yu X, Wang Y, Jiang M, Bierie B, Roy-Burman P, Shen MM et al. Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate 2009; 69: 249-262
13. Jiang YG, Luo Y, He DL, Li X, Zhang LL, Peng T et al. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxiainducible factor-1alpha. Int J Urol 2007; 14: 1034-1039
14. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, Ramirez N et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009; 28: 2940-2947
15. Stankovic S, Konjevic G, Gopcevic K, Jovic V, Inic M, Jurisic V. Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathol Res Pract 2010; 206: 241-247
16. Shah FD, Shukla SN, Shah PM, Shukla HK, Patel PS. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer 2009; 46: 194-202
17. Kossakowska AE, Edwards DR, Prusinkiewicz C, Zhang MC, Guo D, Urbanski SJ. Interleukin-6 Regulation of Matrix Metalloproteinase (MMP-2 and MMP-9) and Tissue Inhibitor of Metalloproteinase (TIMP-1) Expression in Malignant Non- Hodgkin's Lymphomas. Blood 1999; 94: 2080-2089
18. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M et al. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. AM J Pathol 2005; 166: 1173-1186
19. Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L et al. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer 2008; 60: 534-541
20. Troyer DA, Tang Y, Bedolla R, Adhvaryu SG, Thompson IM, Abboud-Werner S et al. Characterization of PacMetUT1, a recently isolated human prostate cancer cell line. Prostate 2008; 68: 883-892
21. Sobel RE, Yuzhuowang A. Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells. In VitroCell Dev Biol (2006); 42: 33-39
22. Rohrmann S, Shiels M, Lopez DS, Rifai N, Nelson WG, Kanarek N et al. Body fatness and sex steroid hormone concentrations in US men: results from NHANES III. Cancer Causes Control (2011); 22: 1141-1151
23. Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Morselli Labate AM, Fabbri R et al. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism (1991); 4: 101-104
24. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 63-69
25. Kane CJ, Im R, Amling CL, Presti Jr JC, Aronson WJ, Terris MK et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: Results from the SEARCH Database. Urology 2010; 76: 695-700
26. López Fontana CM, Recalde Rincón GM, Messina Lombino D, Uvilla Recupero AL, Pérez Elizalde RF, López Laur JD. Body mass index and diet affect prostate cancer development. Actas Urol Esp 2009; 33: 741-746
27. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti Jr JC, Amling CL et al. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2009; 115: 5263-5271
28. Tam L, McGlynn LM, Traynor P, Mukherjee R, Bartlett JM, Edwards J. Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancer. Br J Cancer 2007; 97: 378-383
29. DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB et al. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 2002; 52: 123-129
30. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L et al. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008; 68: 6762-6769
31. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96: 939-949
32. Lamarre NS, Ruggieri Sr MR, Braverman AS, Gerstein MI, Mydlo JH. Effect of obese and lean Zucker rat sera on human and rat prostate cancer cells: implications in obesity-related prostate tumor biology. Urology 2007; 69: 191-195